Syndax Pharmaceuticals, Inc. (SNDX) AI Stock Analysis

Syndax Pharmaceuticals, Inc., based in Waltham, Massachusetts, is a clinical-stage biopharmaceutical firm advancing targeted oncology therapies. Its primary pipeline candidates include SNDX-5613, which is in phase 1/2 trials targeting Menin and mixed lineage leukemia 1 protein interactions for leukemia indications, and SNDX-6352 (axatilimab), a monoclonal antibody blocking the CSF-1 receptor for chronic graft versus host disease. The company is also developing Entinostat and holds partnerships with organizations such as the National Cancer Institute, the Eastern Cooperative Oncology Group, and Kyowa Hakko Kirin Co., Ltd.

Syndax's financial trajectory has featured notable top-line volatility alongside substantial research investments. After dropping to $23.7M in FY2024, revenue climbed 627.8% to $172.4M in FY2025, supported by a 5-year revenue CAGR of 157.7% from FY2019 to FY2025. R&D expenses reached $258.8M in FY2025, contributing to an operating margin of -158.4% and a net loss of -$285.4M, or -$3.29 per share. For the trailing twelve months ended June 30, 2026, revenue stood at $252.3M with quarterly revenue growing 91.8% year-over-year, while TTM net margin was -87.5% and EPS was -$2.52.

As of June 30, 2026, Syndax held $547.9M in cash and short-term investments against total debt of $589.4M, resulting in net debt of $41.5M. The company maintains short-term liquidity with a current ratio of 6.77, though its debt-to-equity ratio stood at 39.03 on shareholders' equity of $15.1M. Operating cash flow was -$323.0M and free cash flow was -$323.2M in FY2025, with capital expenditures of $187,000. Additionally, the company's share count increased 67.4% over five years.

Syndax trades at a price-to-sales multiple of 4.6x, compared to 4.1x for the median of its US-listed Healthcare peers. Its enterprise value of $1.61B represents an EV-to-revenue multiple of 6.4x. The stock has underperformed broader markets, falling 14.3% over the past year and 38.6% year-to-date, compared to a 16.8% 1-year gain for the S&P 500 (SPY). Over a 5-year period, the stock declined 30.6% while the S&P 500 gained 83.0%.

Wall Street coverage includes 10 Strong Buy and 2 Buy ratings, with zero Hold or Sell recommendations. The mean price target is $37.27, representing a 188.9% premium over the October 16, 2026 closing price of $12.90. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $314.1M and an EPS of -$1.98. Syndax beat EPS estimates in 2 of the past 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Syndax Pharmaceuticals, Inc. (SNDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SNDX income statement, SNDX balance sheet, SNDX key metrics, SNDX analyst forecast, SNDX chart. See the SNDX stock overview for the latest quote and news.